 SAN DIEGO, April 12, 2021 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, today announced data from its ongoing Phase 1b2 trial that demonstrate the continued robust patient response to treatment with onvansertib and progression-free survival when combined with standard-of-care therapy in second line KRAS-mutated metastatic colorectal cancer mCRC. Patients enrolled in the ongoing Phase 1b2 trial receive onvansertib in combination with standard-of-care FOLFIRI and Avastin bevacizumab. 